| First Author | Wu QQ | Year | 2011 |
| Journal | Am J Physiol Renal Physiol | Volume | 300 |
| Issue | 5 | Pages | F1180-92 |
| PubMed ID | 21289052 | Mgi Jnum | J:171471 |
| Mgi Id | MGI:4949993 | Doi | 10.1152/ajprenal.00353.2010 |
| Citation | Wu QQ, et al. (2011) Bardoxolone methyl (BARD) ameliorates ischemic AKI and increases expression of protective genes Nrf2, PPAR{gamma}, and HO-1. Am J Physiol Renal Physiol 300(5):F1180-92 |
| abstractText | Ischemic acute kidney injury (AKI) triggers expression of adaptive (protective) and maladaptive genes. Agents that increase expression of protective genes should provide a therapeutic benefit. We now report that bardoxolone methyl (BARD) ameliorates ischemic murine AKI as assessed by both renal function and pathology. BARD may exert its beneficial effect by increasing expression of genes previously shown to protect against ischemic AKI, NF-E2-related factor 2 (Nrf2), peroxisome proliferator-activated receptor-gamma (PPARgamma), and heme oxygenase 1 (HO-1). Although we found that BARD alone or ischemia-reperfusion alone increased expression of these genes, the greatest increase occurred after the combination of both ischemia-reperfusion and BARD. BARD had a different mode of action than other agents that regulate PPARgamma and Nrf2. Thus we report that BARD regulates PPARgamma, not by acting as a ligand but by increasing the amount of PPARgamma mRNA and protein. This should increase ligand-independent effects of PPARgamma. Similarly, BARD increased Nrf2 mRNA; this increased Nrf2 protein by mechanisms in addition to the prolongation of Nrf2 protein half-life previously reported. Finally, we localized expression of these protective genes after ischemia and BARD treatment. Using double-immunofluorescence staining for CD31 and Nrf2 or PPARgamma, we found increased Nrf2 and PPARgamma on glomerular endothelia in the cortex; Nrf2 was also present on cortical peritubular capillaries. In contrast, HO-1 was localized to different cells, i.e., tubules and interstitial leukocytes. Although Nrf2-dependent increases in HO-1 have been described, our data suggest that BARD's effects on tubular and leukocyte HO-1 during ischemic AKI may be Nrf2 independent. We also found that BARD ameliorated cisplatin nephrotoxicity. |
